General Information of Drug (ID: DM2U16Z)

Drug Name
ANAVEX 1007 Drug Info
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Preclinical [1]
Pancreatic cancer 2C10 Preclinical [1]
Prostate cancer 2C82.0 Preclinical [1]
Cross-matching ID
TTD Drug ID
DM2U16Z

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MIN-101 DMCJY35 Schizophrenia 6A20 Phase 3 [2]
CT1812 DMBRKZ7 Alzheimer disease 8A20 Phase 2 [3]
Isoindoline derivative 5 DMIUTQW N. A. N. A. Patented [4]
Isoindoline derivative 3 DM2MYL9 N. A. N. A. Patented [4]
Isoindoline derivative 4 DMP1NKI N. A. N. A. Patented [4]
Isoindoline derivative 2 DMTE0S3 N. A. N. A. Patented [4]
Isoindoline derivative 1 DMD19QC N. A. N. A. Patented [4]
Benzamide derivative 9 DMVFSJZ N. A. N. A. Patented [4]
Benzamide derivative 10 DM9PKU2 N. A. N. A. Patented [4]
PMID30185082-Compound-57 DMNDF1Z N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dextromethorphan DMUDJZM Allergic rhinitis CA08.0 Approved [5]
Dextromethorphan Polistirex DMEHCY5 Dry cough MD12 Approved [6]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [7]
AVP-786 DMV1SOR Alzheimer disease 8A20 Phase 3 [8]
ADX N05 DMLBYRA Mood disorder 6A60-6E23 Phase 3 [9]
Igmesine DMH97XA Major depressive disorder 6A70.3 Phase 2 [10]
OPC-14523 DMB1WF3 Bulimia nervosa 6B81 Phase 2 [11]
ANAVEX 2-73 DM67OU4 Alzheimer disease 8A20 Phase 1 [1]
SSR-125047 DMSUFW6 Schizophrenia 6A20 Phase 1 [12]
SA-5845 DM6XZRL Central nervous system disease 8A04-8D87 Phase 1 [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor sigma 1 (OPRS1) TT5TPI6 SGMR1_HUMAN Agonist [1]
Sigma intracellular receptor 2 (TMEM97) TT9NXW4 SGMR2_HUMAN Agonist [1]

References

1 2011 Pipeline of Anavex.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
5 Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
8 Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
9 Clinical pipeline report, company report or official report of SK BioPhamaceuticals.
10 Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther. 2006 Jun;317(3):1307-19.
11 Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88.
12 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
13 Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med. 2004 Nov;45(11):1939-45.